- Home
- ATEX vs CDXC Comparison
ATEX vs CDXC Comparison
Compare ATEX & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEX
- CDXC
- Stock Information
- Founded
- ATEX 1997
- CDXC 1999
- Country
- ATEX United States
- CDXC United States
- Employees
- ATEX N/A
- CDXC N/A
- Industry
- ATEX Telecommunications Equipment
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- ATEX Telecommunications
- CDXC Health Care
- Exchange
- ATEX Nasdaq
- CDXC Nasdaq
- Market Cap
- ATEX 623.7M
- CDXC 546.9M
- IPO Year
- ATEX N/A
- CDXC N/A
- Fundamental
- Price
- ATEX $33.72
- CDXC $7.44
- Analyst Decision
- ATEX Strong Buy
- CDXC Strong Buy
- Analyst Count
- ATEX 2
- CDXC 2
- Target Price
- ATEX $68.00
- CDXC $8.00
- AVG Volume (30 Days)
- ATEX 110.1K
- CDXC 3.0M
- Earning Date
- ATEX 11-13-2024
- CDXC 10-31-2024
- Dividend Yield
- ATEX N/A
- CDXC N/A
- EPS Growth
- ATEX N/A
- CDXC N/A
- EPS
- ATEX N/A
- CDXC 0.02
- Revenue
- ATEX $5,607,000.00
- CDXC $91,668,000.00
- Revenue This Year
- ATEX $58.60
- CDXC $18.64
- Revenue Next Year
- ATEX $5.40
- CDXC $20.72
- P/E Ratio
- ATEX N/A
- CDXC $383.52
- Revenue Growth
- ATEX 97.01
- CDXC 9.95
- 52 Week Low
- ATEX $29.12
- CDXC $1.32
- 52 Week High
- ATEX $42.41
- CDXC $7.85
- Technical
- Relative Strength Index (RSI)
- ATEX 50.28
- CDXC 71.43
- Support Level
- ATEX $32.55
- CDXC $6.80
- Resistance Level
- ATEX $34.51
- CDXC $7.85
- Average True Range (ATR)
- ATEX 1.18
- CDXC 0.55
- MACD
- ATEX 0.07
- CDXC 0.04
- Stochastic Oscillator
- ATEX 60.27
- CDXC 82.25
About ATEX Anterix Inc.
Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.